A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
Recruiting now · Phase 1/Phase 2
Conditions studied: Lupus Erythematosus, Systemic
In brief
This is a Phase 1b/2, single-arm, open-label, multi-center, clinical study of AZD0120, a CD19/BCMA dual CAR T cell therapy, to evaluate the safety, tolerability, and efficacy in adult participants with refractory Systemic Lupus Erythematosus.
Key facts
- Study ID
- NCT06897930
- Run by
- AstraZeneca
- People needed
- 150
- Starts
- 2025-04-21
- Expected to finish
- 2029-05-01
- Last updated by the study team
- 2026-07-08
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Syracuse, New York, United States (enrolling)
- Research Site — Chapel Hill, North Carolina, United States (enrolling)
- Research Site — Charlotte, North Carolina, United States (enrolling)
- Research Site — Boston, Massachusetts, United States (enrolling)
- Research Site — Seattle, Washington, United States (enrolling)
- Research Site — Seattle, Washington, United States (enrolling)
- Research Site — Darlinghurst, Australia (enrolling)
- Research Site — St Louis, Missouri, United States (enrolling)
- Research Site — New York, New York, United States (enrolling)
- Research Site — Toronto, Canada
- Research Site — Stanford, California, United States
- Research Site — Tampa, Florida, United States
- Research Site — Atlanta, Georgia, United States
- Research Site — Chicago, Illinois, United States
- Research Site — Bethesda, Maryland, United States
- Research Site — Richmond, Virginia, United States
- Research Site — Melbourne, Australia
- Research Site — San Francisco, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.